Laurel Wealth Advisors LLC Has $5.55 Million Position in DexCom, Inc. $DXCM

Laurel Wealth Advisors LLC lifted its position in DexCom, Inc. (NASDAQ:DXCM) by 8,629.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 63,548 shares of the medical device company’s stock after acquiring an additional 62,820 shares during the period. Laurel Wealth Advisors LLC’s holdings in DexCom were worth $5,547,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in DexCom by 1.8% in the second quarter. Vanguard Group Inc. now owns 48,322,405 shares of the medical device company’s stock valued at $4,218,063,000 after purchasing an additional 866,506 shares in the last quarter. Jennison Associates LLC grew its holdings in shares of DexCom by 9.4% in the 2nd quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company’s stock valued at $1,005,367,000 after buying an additional 994,300 shares during the period. Geode Capital Management LLC increased its position in shares of DexCom by 3.4% in the 2nd quarter. Geode Capital Management LLC now owns 10,766,356 shares of the medical device company’s stock valued at $936,100,000 after buying an additional 358,617 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in DexCom by 22.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company’s stock worth $691,336,000 after buying an additional 1,868,241 shares during the period. Finally, Nuveen LLC bought a new position in DexCom during the first quarter worth about $554,893,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Buying and Selling

In related news, EVP Sadie Stern sold 1,466 shares of DexCom stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $80.00, for a total value of $117,280.00. Following the sale, the executive vice president owned 105,223 shares of the company’s stock, valued at approximately $8,417,840. The trade was a 1.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Richard Alexander Collins sold 3,948 shares of the stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $55.17, for a total value of $217,811.16. Following the transaction, the director directly owned 37,994 shares of the company’s stock, valued at $2,096,128.98. This trade represents a 9.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 9,999 shares of company stock worth $619,391 over the last three months. Company insiders own 0.32% of the company’s stock.

DexCom Price Performance

NASDAQ DXCM opened at $62.53 on Thursday. The firm’s 50 day moving average is $64.66 and its 200-day moving average is $76.13. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $24.39 billion, a PE ratio of 43.42, a price-to-earnings-growth ratio of 1.43 and a beta of 1.40. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $93.25.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, beating analysts’ consensus estimates of $0.57 by $0.04. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The business had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.18 billion. During the same quarter last year, the firm earned $0.45 earnings per share. The firm’s revenue for the quarter was up 21.6% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. Equities research analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

DXCM has been the subject of several recent analyst reports. Evercore ISI initiated coverage on DexCom in a report on Tuesday. They issued an “in-line” rating and a $68.00 price target for the company. Oppenheimer cut DexCom from an “outperform” rating to a “market perform” rating in a research note on Monday, September 8th. Piper Sandler set a $75.00 price target on shares of DexCom and gave the company a “buy” rating in a research note on Friday, October 31st. Royal Bank Of Canada reduced their price target on shares of DexCom from $100.00 to $85.00 and set an “outperform” rating for the company in a report on Friday, October 31st. Finally, BTIG Research dropped their price objective on shares of DexCom from $109.00 to $85.00 and set a “buy” rating on the stock in a report on Friday, October 31st. Three research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, DexCom currently has an average rating of “Moderate Buy” and an average target price of $86.73.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.